ACRV icon

Acrivon Therapeutics
ACRV

Overview Fund Activity

48 hedge funds and large institutions have $109M invested in Acrivon Therapeutics in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 5 closing their positions.

Holders
48
Holders Change
+7
Holders Change %
+17.07%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
12
Increased
14
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
1
BlackRock
New York
$5.32M
2
Renaissance Technologies
2
Renaissance Technologies
New York
$734K
3
Millennium Management
3
Millennium Management
New York
$683K
4
Geode Capital Management
4
Geode Capital Management
Massachusetts
$1.74M
5
BBA
5
Baker Bros. Advisors
New York
$378K

Top Sellers

1
NMC
1
NEA Management Company
Maryland
$0
2
Federated Hermes
2
Federated Hermes
Pennsylvania
$0
3
Morgan Stanley
3
Morgan Stanley
New York
$123K
4
Jacobs Levy Equity Management
4
Jacobs Levy Equity Management
New Jersey
$0
5
JPMorgan Chase & Co
5
JPMorgan Chase & Co
New York
$35.5K
Name Market Value Shares Shares
Change 		Shares
Change %
Qube Research & Technologies (QRT)
51
Qube Research & Technologies (QRT)
United Kingdom
– – -260 Closed
CFGS
52
Concourse Financial Group Securities
Alabama
– – – –
Carson Wealth (CWM LLC)
53
Carson Wealth (CWM LLC)
Nebraska
$0 3 +3 New
CAL
54
Capital Advisors Ltd
Ohio
$0 48 +48 New
1 2
3